[Immunological indicators in children with laryngeal papillomatosis and possible ways of immunocorrection].
Garashchenko. T I TI; Markova. T P TP; Chuvirov. D G DG
Key Findings
- Children with laryngeal papillomatosis showed suppressed T‑cell immunity and reduced phagocytosis, worsening with disease progression
- Markers of nonspecific resistance (properdin, lysozyme, complement, secretory IgA) were low, indicating weak local immunity
- A combined regimen that included thymalin shortened basic treatment duration and extended remission by 2.5‑3‑fold
Practical Outcomes
- For biohackers, thymalin shows some promise as an immune‑boosting add‑on, but the evidence is limited to a specific pediatric disease. It’s not a proven longevity or performance tool yet, and any self‑experiment should consider the lack of broader safety and efficacy data.
Summary
The study looked at kids with a throat condition called laryngeal papillomatosis and found their immune systems were weak. Adding the peptide thymalin (along with other drugs) to the treatment made the standard therapy shorter and kept the disease away for a longer time, about 2.5‑3 times longer than usual.
Abstract
Clinicoimmunological characteristics were followed up in the course of laryngeal papillomatosis (LP) in 96 children. It was found that they had suppressed T-cell immunity, phagocytosis which still worsen with the disease aggravation and recurrences. A decrease in nonspecific resistance, properdin, lysozyme, complement and secretory IgA indicated impairment of nasopharyngeal and laryngeal local immunity. A scheme of combined treatment is proposed incorporating basic therapy with reaferon, systemic immunomodulators (thymalin, T-activin) and local immunocorrection. Such approach reduced the time of basic treatment and prolonged remission 2.5-3-fold.
Study Information
pubmed
1996